AVP and diabetes mellitus: In people with diabetes, independent of fasting glucose and hemoglobin A1c, plasma copeptin significantly interacts with diabetes to predict 33% greater risk of coronary artery disease, 62% greater risk of heart failure, and 32% greater risk of death from diabetes [34].